Search Clinical Trials in the European Union

Duration
≤5 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
401-420 of 525 trials

Iron Deficiency Anemia in Children: Ferumoxytol Study

We are testing the safety and effectiveness of the drug ferumoxytol for children with iron deficiency anemia. This study compares it to an existing treatment to see how well it works.

Iron Deficiency Anemia≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHematologyPediatrics

Lung Fibrosis in Systemic Rheumatic Diseases: Imaging Study

We are investigating whether advanced imaging can help identify early signs of lung fibrosis in patients with systemic rheumatic diseases. This may help us understand lung function changes and improve patient care.

Connective Tissue Disease with Risk of Lung Disease1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPulmonologyRheumatology

Prucalopride for Refractory Gastro-Esophageal Reflux Disease

We are testing a new medication for patients with GERD who still have symptoms despite taking standard treatments. The goal is to see if this drug can improve their reflux symptoms.

Gastro-esophageal Reflux Disease (GERD)≤3 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Knee Osteoarthritis: Bovine vs. Marine Chondroitin Sulfate

We are comparing two types of chondroitin sulfate tablets to see if they help reduce pain and improve function in people with knee osteoarthritis. This study will also look at how these treatments affect quality of life and safety.

Knee Osteoarthritis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOrthopedics and TraumatologyRheumatology

Chronic Urticaria: Testing Remibrutinib

We are exploring whether remibrutinib can help adults with Chronic Urticaria manage their symptoms better than a placebo. The study also looks at the safety of this new treatment and its effects on quality of life.

Chronic Urticaria≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteAllergologyDermatology

Group B Streptococcus Vaccine: GBS NN/NN2 in Pregnant Women

We are studying the GBS NN/NN2 vaccine to see how long the immune response lasts and how safe it is when given as a booster during a new pregnancy. We also want to understand how well antibodies are passed from mothers to their babies.

Group B Streptococcus Neonatal Sepsis>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboGynecology and ObstetricsInfectious Diseases

Genital Herpes: IM-250 Treatment Study

We are investigating a new medication, IM-250, for people with recurrent genital herpes to see if it can help reduce outbreaks. The study will also look at the safety of this treatment when given weekly.

Genital Herpes≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementDermatologyInfectious Diseases

Post-COVID-19 Condition: Plitidepsin Study

We are investigating whether plitidepsin can improve health outcomes for adults with post-COVID-19 Condition. The study will compare its effects to a placebo on symptoms and overall well-being.

Post-COVID-19 Syndrome3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteCardiologyDiabetologyEndocrinologyGastroenterologyHematologyInfectious DiseasesInternal MedicineNeurologyPsychiatryPulmonologyRheumatology

Immune Thrombocytopenia: Dexamethasone vs. IVIg

We are studying whether oral dexamethasone is as effective as intravenous immunoglobulin combined with prednisone for adults with immune thrombocytopenia experiencing bleeding. This research may help identify a more convenient treatment option.

Immune Thrombocytopenia>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Bariatric Surgery: Metformin for Diabetes Management

We are studying whether adding metformin to standard care helps people who had bariatric surgery stay diabetes-free longer. This trial focuses on former type 2 diabetes patients and their overall health and quality of life.

Type 2 Diabetes>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Glycerol Phenylbutyrate for Pyruvate Dehydrogenase Deficiency

We are studying whether Glycerol Phenylbutyrate can help reduce fatigue and improve quality of life for patients with Pyruvate Dehydrogenase Deficiency. The trial will also assess its safety and effects on neurodevelopmental symptoms.

Pyruvate Dehydrogenase Deficiency1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyGastroenterologyNeurology

Pancreatic and Bile Duct Cancer: 68Ga-FAPI-46 PET Imaging Study

We are testing a new imaging method to better visualize pancreatic and bile duct cancers. This study aims to see how accurately it detects cancer and monitors treatment response.

Cholangiocarcinoma (Bile Duct Cancer)Pancreatic Carcinoma (Pancreatic Cancer)>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Type 2 Diabetes: Personalized Treatment Study

We are exploring how different diabetes medications work for patients based on their insulin response. The goal is to find biomarkers that help tailor treatments for better management of type 2 diabetes.

Type 2 Diabetes1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyInternal Medicine

Clebopride for the Treatment of Rumination Syndrome

We are studying whether clebopride can improve symptoms in people suspected of having rumination syndrome. The trial compares its effects to a placebo to see how well it works.

Rumination Syndrome≤3 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Chronic Kidney Disease: Optimizing Tacrolimus Dosage with Genetic Testing

We are studying whether a genetic testing strategy can help tailor tacrolimus dosing for patients with chronic kidney disease before kidney transplantation. This may improve treatment outcomes and reduce side effects.

Kidney Transplant1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineNephrology

RSV Hospitalization Prevention: Abrysvo® Vaccine Study

We are studying whether the Abrysvo® vaccine can help prevent hospitalizations from RSV in adults aged 18 and older, especially those 60 and above. This research aims to improve respiratory health outcomes in older adults.

RSV Infection6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Epstein-Barr Virus Diseases: Tabelecleucel Treatment

We are studying a new treatment called tabelecleucel for individuals with Epstein-Barr virus-associated diseases. The goal is to see if it can improve health outcomes compared to current options.

EBV-Related Lymphoproliferative Disorder>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyInfectious DiseasesOncology

Immune-Related Rheumatological Events in Cancer Patients

We are collecting data on how to better diagnose and manage joint and muscle issues caused by cancer treatments. This study involves multiple centers to improve care for patients receiving checkpoint inhibitors.

Cancer (all types)>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyRheumatology

Rheumatoid Arthritis: Targeted Therapy vs. Triple Therapy

We are studying whether targeted therapies are more effective than a combination of three other medications for patients with rheumatoid arthritis who haven't responded to standard treatments. The trial also looks at safety and quality of life.

Rheumatoid ArthritisConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Sjögren's Syndrome: Stem Cell Treatment for Dry Mouth

We are studying whether injecting stem cells into the salivary glands can improve saliva flow in patients with dry mouth from Sjögren's syndrome. This trial will also assess safety and other effects on saliva quality.

Sjögren's Syndrome≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesOrthopedics and TraumatologyRheumatology